Pulse Biosciences CS (PLSE) Stock Price, Quote & News

Company Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cyc...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 510 906 4600

Website: www.pulsebiosciences.com

Address:

601 Brickell Key Drive, Suite 1080, Miami, United States

ThePoorMillionaire Sep. 13 at 12:14 AM

$PLSE you will be rich loading up at these levels

0 · Reply

TruthBroker2 Sep. 12 at 5:53 PM

$PLSE

0 · Reply

Storm_Spot_52 Sep. 12 at 5:35 PM

$PLSE NXXT scaling story reminds me of early multibaggers, execution first then rerate, trend traders love this structure.

0 · Reply

TruthBroker2 Sep. 12 at 5:32 PM

$PLSE Bye Bye Darrin He Gone

0 · Reply

Breadmaster Sep. 12 at 5:00 PM

$PLSE oof

0 · Reply

Jagr1 Sep. 12 at 4:51 PM

$PLSE Something is happening. Anyone? There is some truth to what is said.

1 · Reply

Jagr1 Sep. 12 at 4:51 PM

$PLSE

0 · Reply

TruthBroker2 Sep. 12 at 4:20 PM

$PLSE Its not True Darrin sold 30k shares in june but still has 120k shares

1 · Reply

STOCKieNEWB Sep. 12 at 3:58 PM

$PLSE why hold when you know that its own employees are selling.

0 · Reply

TruthBroker2 Sep. 12 at 3:54 PM

$PLSE

0 · Reply

Pulse Biosciences' nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting

Sep 8, 2025, 7:00 AM EDT - 4 days ago

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

Sep 4, 2025, 7:00 AM EDT - 8 days ago

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 2, 2025, 7:00 AM EDT - 10 days ago

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

Aug 26, 2025, 7:00 AM EDT - 17 days ago

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Aug 12, 2025, 9:06 PM EDT - 4 weeks ago

Pulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 4 weeks ago

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

Aug 1, 2025, 7:00 AM EDT - 6 weeks ago

Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

Jul 29, 2025, 4:05 PM EDT - 6 weeks ago

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

May 10, 2025, 11:02 PM EDT - 4 months ago

Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 4 months ago

Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

May 6, 2025, 4:05 PM EDT - 4 months ago

Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

May 1, 2025, 7:00 AM EDT - 4 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting

Apr 24, 2025, 4:05 PM EDT - 5 months ago

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

Apr 23, 2025, 7:00 AM EDT - 5 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting

Mar 27, 2025, 7:46 PM EDT - 6 months ago

Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 6 months ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

Mar 26, 2025, 4:05 PM EDT - 6 months ago

Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

Mar 7, 2025, 8:00 AM EST - 6 months ago

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

Feb 20, 2025, 4:05 PM EST - 7 months ago

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference

Feb 4, 2025, 8:00 AM EST - 7 months ago

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

Jan 30, 2025, 8:00 AM EST - 8 months ago

Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting

Jan 21, 2025, 7:00 AM EST - 8 months ago

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Jan 13, 2025, 7:00 AM EST - 8 months ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Jan 10, 2025, 8:00 AM EST - 8 months ago

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

Jan 3, 2025, 9:00 AM EST - 9 months ago

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 4:30 PM EST - 9 months ago

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Dec 19, 2024, 8:00 AM EST - 9 months ago

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

Dec 17, 2024, 8:00 AM EST - 9 months ago

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Oct 31, 2024, 2:25 PM EDT - 11 months ago

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Oct 30, 2024, 9:42 PM EDT - 11 months ago

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:05 PM EDT - 11 months ago

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Oct 30, 2024, 4:02 PM EDT - 11 months ago

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Oct 21, 2024, 8:00 AM EDT - 11 months ago

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

Aug 12, 2024, 6:50 PM EDT - 1 year ago

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

Jul 8, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Jul 3, 2024, 2:44 PM EDT - 1 year ago

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

May 20, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

May 16, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

May 14, 2024, 4:05 PM EDT - 1 year ago

Pulse Biosciences Enhances Executive Leadership Team

May 11, 2024, 1:29 PM EDT - 1 year ago

Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript

May 9, 2024, 8:00 AM EDT - 1 year ago

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

ThePoorMillionaire Sep. 13 at 12:14 AM

$PLSE you will be rich loading up at these levels

0 · Reply

TruthBroker2 Sep. 12 at 5:53 PM

$PLSE

0 · Reply

Storm_Spot_52 Sep. 12 at 5:35 PM

$PLSE NXXT scaling story reminds me of early multibaggers, execution first then rerate, trend traders love this structure.

0 · Reply

TruthBroker2 Sep. 12 at 5:32 PM

$PLSE Bye Bye Darrin He Gone

0 · Reply

Breadmaster Sep. 12 at 5:00 PM

$PLSE oof

0 · Reply

Jagr1 Sep. 12 at 4:51 PM

$PLSE Something is happening. Anyone? There is some truth to what is said.

1 · Reply

Jagr1 Sep. 12 at 4:51 PM

$PLSE

0 · Reply

TruthBroker2 Sep. 12 at 4:20 PM

$PLSE Its not True Darrin sold 30k shares in june but still has 120k shares

1 · Reply

STOCKieNEWB Sep. 12 at 3:58 PM

$PLSE why hold when you know that its own employees are selling.

0 · Reply

TruthBroker2 Sep. 12 at 3:54 PM

$PLSE

0 · Reply

Easteregg Sep. 12 at 3:25 PM

$PLSE Holy shit! https://x.com/WhiteResearch/status/1966522936166093251

1 · Reply

TruthBroker2 Sep. 12 at 11:05 AM

$PLSE

1 · Reply

ZacksResearch Sep. 11 at 4:30 PM

$PLSE just hit a major milestone with FDA's approval of its Investigational Device Exemption (IDE) to initiate the NANOCLAMP AF study! 🚀 The IDE approval paves the way for PLSE’s innovative nsPFA Cardiac Surgery System, potentially offering a safer alternative to traditional methods. This could be a game-changer in the atrial fibrillation market. Discover PLSE's growth potential and what it means for investors 👉 https://www.zacks.com/stock/news/2750293/pulse-biosciences-gets-fda-ide-nod-for-atrial-fibrillation-study?cid=sm-stocktwits-2-2750293-body-12061&ADID=SYND_STOCKTWITS_TWEET_2_2750293_BODY_12061

0 · Reply

ZacksResearch Sep. 11 at 3:30 PM

$PLSE just scored a key FDA green light 🚀 The IDE approval pushes forward its NANOCLAMP AF study, advancing nsPFA tech as a potential new option in atrial fibrillation surgery. Full details here 👉 https://www.zacks.com/stock/news/2750293/pulse-biosciences-gets-fda-ide-nod-for-atrial-fibrillation-study?cid=sm-stocktwits-2-2750293-teaser-12057&ADID=SYND_STOCKTWITS_TWEET_2_2750293_TEASER_12057

0 · Reply

Easteregg Sep. 10 at 7:25 PM

$PLSE $SMMT Bob in 3 years

2 · Reply

TruthBroker2 Sep. 10 at 11:16 AM

$PLSE

0 · Reply

Easteregg Sep. 9 at 1:53 PM

$SMMT $PLSE WHERE THE F IS BOB??!??

0 · Reply

TruthBroker2 Sep. 9 at 10:37 AM

$PLSE

0 · Reply

DARKP00L Sep. 8 at 5:46 PM

$PLSE 12:56 on Sep. 08 2025 PLSE stock has given up its prior gain. Pulse Biosciences shares were trading higher after the company announced that the FDA granted approval for its Investigational Device Exemption, allowing Pulse Biosciences to proceed with the initiation of its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for the treatment of atrial fibrillation. #tradeideas

0 · Reply

prismmarketview Sep. 8 at 2:05 PM

(NASDAQ: $PLSE) #PulseBiosciences wins FDA IDE clearance to begin a pivotal trial of its nsPFA Cardiac Surgery System (NANOCLAMP AF) for atrial fibrillation. The study will enroll up to 136 patients across ~20 sites, moving the tech closer to commercialization. https://prismmarketview.com/pulse-biosciences-receives-fda-ide-clearance-for-nspfa-cardiac-surgery-trial-in-atrial-fibrillation/

0 · Reply

Easteregg Sep. 8 at 12:17 PM

$SMMT $PLSE Team Duggan

0 · Reply

TruthBroker2 Sep. 8 at 12:00 PM

$PLSE

0 · Reply

Market Cap	1.02B
Revenue (ttm)	0.00
Net Income (ttm)	-53.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	438,300
Avg Vol	165,368
Day's Range	N/A - N/A
Shares Out	67.30M
Stochastic %K	35%
Beta	1.68
Analysts	Sell
Price Target	$22.00